1.2021 -0.008 (-0.65%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.48 | 1-year : | 1.56 |
Resists | First : | 1.27 | Second : | 1.34 |
Pivot price | 1.27 | |||
Supports | First : | 1.15 | Second : | 0.96 |
MAs | MA(5) : | 1.23 | MA(20) : | 1.26 |
MA(100) : | 1.22 | MA(250) : | 1.36 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 15.6 | D(3) : | 28.6 |
RSI | RSI(14): 43 | |||
52-week | High : | 1.75 | Low : | 0.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZTEK ] has closed above bottom band by 4.1%. Bollinger Bands are 43.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.21 - 1.22 | 1.22 - 1.22 |
Low: | 1.15 - 1.16 | 1.16 - 1.17 |
Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Mon, 25 Mar 2024
Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA - The Caledonian-Record
Mon, 11 Mar 2024
Scotia Capital Inc. Has $567000 Position in Zentek Ltd. (NASDAQ:ZTEK) - Defense World
Wed, 13 Dec 2023
Zentek Launches Triera Biosciences Ltd. - Yahoo Finance
Wed, 29 Nov 2023
Zentek Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant - Yahoo Finance
Tue, 21 Nov 2023
Zentek Announces Update on the Albany Graphite Project - Yahoo Finance
Thu, 24 Aug 2023
Zentek Announces Distribution and Supply Agreement with Henry Schein, Inc. - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Instruments & Supplies
|
|
Shares Out | 0 (M) |
Shares Float | 101 (M) |
Held by Insiders | 9.547e+007 (%) |
Held by Institutions | 5.9 (%) |
Shares Short | 95 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.223e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -23 % |
Return on Assets (ttm) | 68.2 % |
Return on Equity (ttm) | -29.2 % |
Qtrly Rev. Growth | 33610 % |
Gross Profit (p.s.) | -21.28 |
Sales Per Share | -57.62 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -9 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.03 |
Price to Cash Flow | 4.69 |
Dividend | 0 |
Forward Dividend | 86100 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |